Scholar Rock Holding (SRRK) is back in focus after the FDA accepted its Biologics License Application for apitegromab to treat spinal muscular atrophy, setting up an important regulatory decision later this year.

At a share price of US$46.45, Scholar Rock has eased in the short term, with the 1 month share price return down 6.91% and the 3 month share price return down 2.46%. However, the 1 year total shareholder return of 49.89% and a very large 3 year total shareholder return suggest longer term momentum linked to regulatory milestones such as the apitegromab BLA acceptance and ongoing pipeline progress.

If you are interested in how other healthcare companies tied to advanced technology are trading around catalysts, it may be worth scanning 35 healthcare AI stocks

With the stock trading at US$46.45, a sizeable intrinsic value gap and a discount to the average analyst target suggest potential upside. However, with a key FDA decision ahead, is there still a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 16% Undervalued

Compared with the most followed fair value estimate of $55.07, Scholar Rock’s last close of $46.45 sits at a noticeable discount, with that gap hinging on how apitegromab and the wider pipeline translate into future revenue and earnings.

Scholar Rock Holding currently has no revenue. Analysts are forecasting revenue to reach $398.1 million by March 2029.

If Scholar Rock Holding's profit margin were to converge on the industry average, you could expect earnings to reach $43.4 million (and earnings per share of $0.31) by about March 2029, up from $377.9 million of losses today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $71.9 million in earnings, and the most bearish expecting $353.3 million of losses.

Want to see what kind of revenue ramp, margin shift and future earnings multiple need to line up to get to that fair value? The narrative breaks those assumptions down and shows how they combine into a single target price.

Result: Fair Value of $55.07 (UNDERVALUED)

However, this story still hinges on a smooth FDA and manufacturing outcome, and on apitegromab delivering real world benefits that support the current valuation narrative.

Another View: Multiples Paint a Tougher Picture

The fair value narrative leans on future cash flows, but the simple price tag today tells a different story. On a P/B of 20.1x, Scholar Rock trades at a far higher level than the US Biotechs industry at 2.5x and peer average at 13.4x, which points to meaningful valuation risk if expectations reset.

For a closer look at how this ratio compares with what the numbers imply the market could move towards, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between opportunity and risk, you do not need to wait for the next headline to decide where you stand. Review the balance of potential upsides and concerns in these 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If you want to keep sharpening your watchlist beyond Scholar Rock, do not wait for the next big headline. Instead, scan what the wider market is offering today using focused stock lists.

• Spot potential value opportunities early by reviewing companies featured in the 50 high quality undervalued stocks.
• Prioritise resilience by checking out stocks highlighted in the 71 resilient stocks with low risk scores.
• Hunt for fresh opportunities by scanning the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.